Search This Blog

Tuesday, February 17, 2026

Ocular Therapeutix announces positive topline results from its SOL-1 Phase 3 trial in wet AMD

AXPAXLI meeting a superiority primary endpoint versus aflibercept and the company planning an NDA filing after discussions with the FDA.

https://finviz.com/quote.ashx?t=OCUL&p=d

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)